Systemic Adjuvant Therapy for Patients at High Risk for Recurrent Melanomaenglish
Adult patients with high-risk malignant melanoma who are rendered disease-free following resection. Patients who would now be classified as American Joint Committee on Cancer (AJCC) stage IIB, IIC and III. For this practice guideline, high risk is defined as patients in the following clinical states:
- Primary melanoma with tumour thickness 4.0 mm
- Primary melanoma with in-transit metastases
- Positive sentinel lymph nodes
- Primary melanoma with regional lymph node metastases that are clinically apparent
- Regional lymph node recurrence
- Involved nodes were excised but there was no known primary melanoma
Intended Guideline Users
Clinicians and healthcare providers involved in the management and referral of patients with resected melanoma at high risk for recurrence.
What systemic therapy should clinicians recommend to patients who have been rendered diseasefree following the resection of cutaneous melanomas and who are at high risk for subsequent recurrence?